CARs incorporating VNAR B2, which blocks the interaction between PD-L1 and PD-1, demonstrated effective lysis of PD-L1+ TNBC cells in vitro and tumor regression in xenograft models. This evidence concerns the gene PDCD1 and neoplasm.